Literature DB >> 2783201

Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.

S Lussier-Cacan1, J M Bard, L Boulet, A C Nestruck, A M Grothé, J C Fruchart, J Davignon.   

Abstract

Fenofibrate (300 mg daily) was given to 9 subjects (7 men, 2 women) with dysbetalipoproteinemia type III. The treatment brought about important plasma level reductions in cholesterol (-35%), triglycerides (-56%), VLDL-cholesterol (-63%) and VLDL-triglycerides (-59%). The VLDL-C/TG ratio, which was 0.40 before treatment, was 0.30 after 4 weeks of fenofibrate, still suggestive of type III. LDL-C, when measured by conventional methods, was unchanged but isolation of the IDL (1.006-1.019 g/ml) fraction from the 1.006 g/ml infranatant revealed that true LDL-C levels actually increased in 6 individuals while IDL-C decreased considerably. The total HDL-C increase was mostly due to a 33% HDL3-C change. Apolipoprotein levels were considerably modified, notably apo B, C-III and E which were decreased, as well as the lipoprotein particles containing combinations of these apolipoproteins, namely LpE:B and LpC-III:B. Apo A-I was slightly modified as LpA-I: A-II particle levels increased and LpA-I decreased. There were marked compositional modifications of apo B-containing lipoproteins which corresponded to changes of the whole lipoprotein profile. Some abnormal classes of lipoproteins (e.g., beta-VLDL, dense LDL), characteristic of this disease, tended to disappear and were in some cases replaced by material of different size and density.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783201     DOI: 10.1016/0021-9150(89)90221-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  Apolipoproteins and metabolism in atherosclerosis.

Authors:  A M Gotto
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

Review 2.  The role of fibric acid derivatives in the secondary prevention of coronary heart disease.

Authors:  J Krakoff; B S Vela; E A Brinton
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

3.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

Review 4.  Physical activity and lipoprotein lipid disorders.

Authors:  A Berg; I Frey; M W Baumstark; M Halle; J Keul
Journal:  Sports Med       Date:  1994-01       Impact factor: 11.136

5.  Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Authors:  Min-Jeong Shin; Alka M Kanaya; Ronald M Krauss
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

Review 6.  Gemfibrozil in Combination with Statins-Is It Really Contraindicated?

Authors:  Barbara S Wiggins; Joseph J Saseen; Pamela B Morris
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

7.  Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Authors:  A Hiukka; E Leinonen; M Jauhiainen; J Sundvall; C Ehnholm; A C Keech; M R Taskinen
Journal:  Diabetologia       Date:  2007-07-26       Impact factor: 10.122

8.  Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.

Authors:  M van Dam; M Zwart; F de Beer; A H M Smelt; M H Prins; M D Trip; L M Havekes; P J Lansberg; J J P Kastelein
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

9.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

Authors:  N Vu-Dac; K Schoonjans; V Kosykh; J Dallongeville; J C Fruchart; B Staels; J Auwerx
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

10.  Hypertriglyceridemia.

Authors:  Amanda Brahm; Robert A Hegele
Journal:  Nutrients       Date:  2013-03-22       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.